Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Top Headlines

Pharmaceutical Business Review

GSK, Innoviva’s Relvar Ellipta shows positive effect in non-inferiority lung function study GlaxoSmithKline (GSK) and Innoviva’s non-inferiority lung function study of Relvar Ellipta has showed positive effect in patients with well-controlled asthma. Contract Research & Services > Clinical Trials > News
Cyclacel's leukemia drug for elderly patients fails in phase 3 trial By PBR Staff Writer
Cyclacel Pharmaceuticals’ leukemia drug for elderly patients failed to meet its primary endpoint in a phase 3 study.
Contract Research & Services > Clinical Trials > News ProMetic’s pulmonary fibrosis drug yields positive results in phase 2 trial ProMetic Life Sciences has revealed positive results for PBI-4050 from its open label Phase 2 clinical trial in idiopathic pulmonary fibrosis ("IPF") patients.
Contract Research & Services > Clinical Trials > News Incyte partners with University of Pennsylvania on cancer immunotherapy research Incyte has entered into multi-year research collaboration with the Abramson Cancer Center at the University of Pennsylvania.
Drug Research > Drug Discovery & Development > News
GSK, Innoviva’s Relvar Ellipta shows positive effect in non-inferiority lung function study By PBR Staff Writer
GlaxoSmithKline (GSK) and Innoviva’s non-inferiority lung function study of Relvar Ellipta has showed positive effect in patients with well-controlled asthma.
Contract Research & Services > Clinical Trials > News ImmusanT’s phase 1b trial of celiac disease vaccine finds phase 2 dose regimen ImmusanT has completed a phase 1b clinical trial evaluating the safety and tolerability of Nexvax2 in celiac disease.
Contract Research & Services > Clinical Trials > News PMV Pharma raises $74m for cancer drugs targeting p53 PMV Pharmaceuticals, which is engaged in the discovery and development of p53-targeted small molecule drugs for the treatment of cancer, has completed a $74m Series B financing round.
Drug Research > Drug Discovery & Development > News

Latest News and Insight by Sector

Production & Manufacturing

Abzena signs antibody manufacturing development deal with University College London
Abzena has entered into a manufacturing agreement with University College London (UCL).
Production & Manufacturing > Manufacturing > News
Arix Bioscience raises £100m in IPO
Global healthcare and life science company Arix Bioscience has raised £100m in its Initial Public Offering (IPO) on the main market of the London Stock Exchange.
Production & Manufacturing > Manufacturing > News

Drug Research

Incyte partners with University of Pennsylvania on cancer immunotherapy research
Incyte has entered into multi-year research collaboration with the Abramson Cancer Center at the University of Pennsylvania.
Drug Research > Drug Discovery & Development > News
PMV Pharma raises $74m for cancer drugs targeting p53
PMV Pharmaceuticals, which is engaged in the discovery and development of p53-targeted small molecule drugs for the treatment of cancer, has completed a $74m Series B financing round.
Drug Research > Drug Discovery & Development > News

Inward Investment

New WuXi Life Science to acquire WuXi PharmaTech for $3.3bn
Shanghai-based WuXi PharmaTech has entered into a merger agreement with New WuXi Life Science and its wholly owned subsidiary WuXi Merger, worth a total cash consideration of $3.3bn.
Inward Investment > News
PPF Group acquires minority stake in Cytune Pharma
By PBR Staff Writer
PPF Group, in cooperation with SOTIO has completed acquisition of minority stake in French biotechnology firm Cytune Pharma.
Inward Investment > News

Packaging

Catalent completes acquisition of Australia's Pharmapak
By PBR Staff Writer
US-based Catalent Pharma Solutions has strengthened its ability to provide integrated solutions to customers with the acquisition of Pharmapak Technologies, an Australian pharmaceutical packaging business.
Production & Manufacturing > OTC > News
MP Global Products introduces foam-free packaging for shipment of temperature sensitive pharmaceuticals
MP Global Thermal Packaging Products insulated protective mailers and box liners are specifically designed for temperature control and protection of mail order shipments of temperature sensitive pharma, pet meds, and natural and organic cosmetics.
Packaging > News

Contract Research & Services

Cyclacel's leukemia drug for elderly patients fails in phase 3 trial
By PBR Staff Writer
Cyclacel Pharmaceuticals’ leukemia drug for elderly patients failed to meet its primary endpoint in a phase 3 study.
Contract Research & Services > Clinical Trials > News
ProMetic’s pulmonary fibrosis drug yields positive results in phase 2 trial
ProMetic Life Sciences has revealed positive results for PBI-4050 from its open label Phase 2 clinical trial in idiopathic pulmonary fibrosis ("IPF") patients.
Contract Research & Services > Clinical Trials > News

Automation

Veeva rolls out cloud application to accelerate regulatory submission delivery
Veeva Systems (VEEV) announced a new cloud application dubbed Veeva Vault Submissions Publishing that incorporates publishing capabilities within Veeva Vault RIM to accelerate regulatory submission delivery.
Automation > IT & Software > News
Arven selects GE Healthcare’s manufacturing platform to expand production capacity at Turkish facility
GE Healthcare’s FlexFactory manufacturing platform has been selected to expand production capacity at Arven Pharmaceuticals' facility in Kirklareli, Turkey.
Automation > IT & Software > News

Regulatory Affairs

FDA grants priority review to Pfizer's antibody-drug conjugate for ALL
By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted a priority review designation to Pfizer's anti-CD22 antibody-drug conjugate inotuzumab ozogamicin to treat patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
Regulatory Affairs > News
European Commission conditionally approves Roche’s cancer drug Alecensa
By PBR Staff Writer
Roche's oral ALK inhibitor, Alecensa, has been conditionally approved in the European Union as a monotherapy for anaplastic lymphoma kinase-positive advanced non-small cell lung cancer (NSCLC) in adults who were earlier treated with crizotinib.
Regulatory Affairs > News



Data-Label.co.uk DataLabel have been supplying
the medical industry with labels
for over 10 years

Manufactures of
healthcare packaging
machinery